Tumor-infiltrating Myeloid Cells; Mechanisms, Functional Significance, and Targeting in Cancer Therapy

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2025 Feb 25

PMID 39998754

Authors

Fatemeh Sadat Toghraie

Maryam Bayat

Mahsa Sadat Hosseini

Amin Ramezani

Affiliations

Soon will be listed here.

Abstract

Tumor-infiltrating myeloid cells (TIMs), which encompass tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), and tumor-associated dendritic cells (TADCs), are of great importance in tumor microenvironment (TME) and are integral to both pro- and anti-tumor immunity. Nevertheless, the phenotypic heterogeneity and functional plasticity of TIMs have posed challenges in fully understanding their complexity roles within the TME. Emerging evidence suggested that the presence of TIMs is frequently linked to prevention of cancer treatment and improvement of patient outcomes and survival. Given their pivotal function in the TME, TIMs have recently been recognized as critical targets for therapeutic approaches aimed at augmenting immunostimulatory myeloid cell populations while depleting or modifying those that are immunosuppressive. This review will explore the important properties of TIMs related to immunity, angiogenesis, and metastasis. We will also document the latest therapeutic strategies targeting TIMs in preclinical and clinical settings. Our objective is to illustrate the potential of TIMs as immunological targets that may improve the outcomes of existing cancer treatments.

References

Wang Y, Johnson K, Gatti-Mays M, Li Z . Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol. 2022; 15(1):118. PMC: 9420297. DOI: 10.1186/s13045-022-01335-y. View

Clappaert E, Murgaski A, Van Damme H, Kiss M, Laoui D . Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy. Front Immunol. 2018; 9:2250. PMC: 6186813. DOI: 10.3389/fimmu.2018.02250. View

Peczek P, Gajda M, Rutkowski K, Fudalej M, Deptala A, Badowska-Kozakiewicz A . Cancer-associated inflammation: pathophysiology and clinical significance. J Cancer Res Clin Oncol. 2022; 149(6):2657-2672. PMC: 9579684. DOI: 10.1007/s00432-022-04399-y. View

Hu H, Hang J, Han T, Zhuo M, Jiao F, Wang L . The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumour Biol. 2016; 37(7):8657-64. DOI: 10.1007/s13277-015-4741-z. View

Mouchemore K, Anderson R, Hamilton J . Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J. 2017; 285(4):665-679. DOI: 10.1111/febs.14206. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Wang M, Chen S, He X, Yuan Y, Wei X . Targeting inflammation as cancer therapy. J Hematol Oncol. 2024; 17(1):13. PMC: 10960486. DOI: 10.1186/s13045-024-01528-7. View

Li K, Nie H, Jin R, Wu X . Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy. Front Immunol. 2024; 15:1397005. PMC: 11109455. DOI: 10.3389/fimmu.2024.1397005. View

Qian Y, Yin Y, Zheng X, Liu Z, Wang X . Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities. Biomark Res. 2024; 12(1):1. PMC: 10773124. DOI: 10.1186/s40364-023-00549-7. View

10.

De Zuani M, Xue H, Park J, Dentro S, Seferbekova Z, Tessier J . Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun. 2024; 15(1):4388. PMC: 11116453. DOI: 10.1038/s41467-024-48700-8. View

11.

Biswas S, Sica A, Lewis C . Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol. 2008; 180(4):2011-7. DOI: 10.4049/jimmunol.180.4.2011. View

12.

Kuang D, Zhao Q, Peng C, Xu J, Zhang J, Wu C . Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009; 206(6):1327-37. PMC: 2715058. DOI: 10.1084/jem.20082173. View

13.

Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J . Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010; 70(14):5728-39. DOI: 10.1158/0008-5472.CAN-09-4672. View

14.

Van Dyken S, Locksley R . Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013; 31:317-43. PMC: 3606684. DOI: 10.1146/annurev-immunol-032712-095906. View

15.

Jetten N, Verbruggen S, Gijbels M, Post M, de Winther M, Donners M . Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis. 2013; 17(1):109-18. DOI: 10.1007/s10456-013-9381-6. View

16.

Hashimoto D, Chow A, Noizat C, Teo P, Beasley M, Leboeuf M . Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013; 38(4):792-804. PMC: 3853406. DOI: 10.1016/j.immuni.2013.04.004. View

17.

Italiani P, Boraschi D . From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol. 2014; 5:514. PMC: 4201108. DOI: 10.3389/fimmu.2014.00514. View

18.

Pathria P, Louis T, Varner J . Targeting Tumor-Associated Macrophages in Cancer. Trends Immunol. 2019; 40(4):310-327. DOI: 10.1016/j.it.2019.02.003. View

19.

Gautier E, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S . Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012; 13(11):1118-28. PMC: 3558276. DOI: 10.1038/ni.2419. View

20.

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View